Newron Pharmaceuticals S.p.A. (NWRN.SW) SIX
12.44
-0.64(-4.89%)
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
12.44
-0.64(-4.89%)
Currency In CHF
Sector
Healthcare
Industry
Biotechnology
Employees
22
First IPO Date
December 12, 2006
| Name | Title | Pay | Year Born |
| Stefan Weber | Chief Executive Officer & Executive Director | 441,506 | 1965 |
| Ravi Anand | Chief Medical Officer | 1.23M | 1957 |
| Filippo Moriggia | Vice President of Operations | 0 | N/A |
| Roberto Galli | Chief Financial Officer | 0 | N/A |
| Laura Faravelli | Vice President of Business Development | 0 | N/A |
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.